We have yet to hear from them on this. I think if anyone can bring this to market, ELN would be at the forefront. Remember, natalizumab(Tysabri) was a product of ELN's Alzheimer's research, NOT BIIB's!!
Oral Antegren is probably not possible because it is a complex protein antibody which would be quickly digested into fragments in the gut.
A more realistic (and achievable) goal would be an injectable form of antegren, either IM or subcutaneous. Elan has considerable expertise in this area - I could see this happening - and approval would be realtively quick if there were no significant injection site effects - and dosing was achieved.